HealthCap

HealthCap is a venture capital firm based in Stockholm, Sweden, founded in 1996. Specializing in life sciences, the firm invests in healthcare, biotechnology, pharmaceuticals, nanotechnology, and information technology sectors, primarily focusing on companies located in Europe. With committed capital exceeding €800 million, HealthCap is recognized as one of the largest providers of venture capital within the European life sciences market. The firm operates across both early-stage and late-stage investment segments and has managed three funds, enabling it to make a total of 96 investments, with 31 successful exits to date. HealthCap's investment strategy is supported by its exclusive investment advisor, the Odlander Fredrikson Group.

Forsberg, Anki

Partner

Gunterberg, Jacob

Partner

Staffan Lindstrand

Partner

Max Odlander

Partner

Björn Odlander

Founder and Partner

Samuelsson, Per Anders Göte

Partner

Marten Steen

Partner

Eugen Steiner

Venture Partner

Alex Valcu

Partner

122 past transactions

Tribune Therapeutics

Series A in 2025
Tribune Therapeutics is a preclinical biopharmaceutical company dedicated to developing innovative medicines for the treatment of various fibrotic diseases. The company focuses on creating therapies that target the CCN protein family, a group of signaling proteins that play a crucial role in the development of fibrosis. By concentrating on these specific proteins, Tribune Therapeutics aims to provide effective treatment options for patients suffering from fibrotic conditions.

HelloBetter

Venture Round in 2025
HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

SynOx Therapeutics

Series B in 2024
SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

Kivu Bioscience

Series A in 2024
Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.

ADCendo

Series A in 2024
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

SynOx Therapeutics

Series B in 2024
SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

Aro Biotherapeutics

Series B in 2023
Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

Rampart Bioscience

Series A in 2023
Rampart Bioscience specializes in the development of gene medicines aimed at providing long-lasting treatments for a broad array of diseases. The company has created proprietary development and delivery platforms that enable the production of optimized therapeutics in a non-viral format. By integrating expertise from various scientific disciplines, such as gene delivery, protein sciences, and clinical translation, Rampart Bioscience focuses on assisting patients with genetically driven conditions, ultimately enhancing the effectiveness and safety of therapeutic interventions.

Vicore Pharma

Post in 2023
Vicore Pharma is a clinical-stage pharmaceutical company dedicated to developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company's lead drug candidate, C21, is a small molecule angiotensin II type 2 receptor agonist currently in phase 2a development and has received orphan drug designation in both the EU and the US. C21 is also being explored for potential applications in other rare diseases associated with the AT2 receptor. In addition to its pharmacological efforts, Vicore Pharma is developing Almee, an investigational medical device that employs cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. The company operates from Astra Zeneca’s Bioventurehub in Mölndal.

HelloBetter

Series A in 2023
HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

ADCendo

Series A in 2023
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Hemab

Series B in 2023
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Spruce Biosciences

Post in 2023
Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Carisma Therapeutics

Series C in 2022
Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Pretzel Therapeutics

Series A in 2022
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Ariceum Therapeutics

Series A in 2022
Ariceum Therapeutics is a clinical-stage radiopharmaceutical company that focuses on the detection and targeted treatment of aggressive cancers, particularly neuroendocrine tumors and other challenging malignancies. The company's lead product, 177Lu-satoreotide tetraxetan (Satoreotide), acts as an antagonist of the somatostatin type 2 receptor (SSTR2), which is commonly overexpressed in many neuroendocrine tumors. Ariceum is developing Satoreotide as a theranostic pair, which allows for both the diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, certain aggressive tumors, and childhood cancers. This approach aims to provide treatment options for conditions that currently have limited therapies and poor prognoses, enabling healthcare professionals to deliver more effective treatments with reduced side effects.

Precirix

Series B in 2022
Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

HelloBetter

Series A in 2022
HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

Oncorena

Venture Round in 2021
Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, specifically advanced or metastatic renal cancer. The company is focused on the compound orellanine, a toxin derived from certain mushroom species, which has demonstrated potent anti-tumor activity. Oncorena's primary objective is to confirm the efficacy and clinical benefits of orellanine in targeting renal proximal tubular epithelial cells that have transformed into cancer cells and formed metastases. By harnessing the selective properties of this compound, Oncorena aims to provide effective pharmacological solutions for patients suffering from advanced kidney cancer.

Elsa

Seed Round in 2021
Elsa is a platform for patient-driven research for better drugs, health, and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding of how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives them access to data on their specific disease through the Riskminder foundation and scientific studies at Karolinska Institutet.

HelloBetter

Seed Round in 2021
HelloBetter is a pioneering company in the field of digital therapeutics focused on mental health. Founded in 2015 in Hamburg, Germany, the company offers a range of online psychological training programs designed to address issues such as stress, depression, anxiety, and sleep disorders. Its programs have been validated through 33 randomized controlled trials, and six of them have received approval as prescription digital therapeutics under Germany's DiGA framework, allowing access for over 73 million people at no cost. The company's mission is to empower individuals to manage their mental health in a self-determined manner, utilizing evidence-based approaches. In addition to its therapeutic programs, HelloBetter provides resources like blogs and articles related to psychological health. With recent funding aimed at expanding beyond the DACH region, HelloBetter continues to enhance access to effective digital mental health care on a global scale.

Hemab

Series A in 2021
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Doctrin

Series C in 2021
At Doctrin, they are passionate about improving healthcare. They strive to make patients healthier and happier, and healthcare professionals more effective at work. They achieve this by providing digital tools automating and simplifying as much of the patient journey as possible, for as many patients as possible.

ADCendo

Series A in 2021
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Aro Biotherapeutics

Series A in 2020
Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. Established in 2017, the company aims to enhance treatment options for oncology and immunology by creating small, non-antibody protein scaffolds. These Centyrins can be engineered as multi-specific therapeutics, enabling innovative mechanisms of action. They are designed to improve efficacy and safety profiles for patients suffering from cancer and other serious diseases, while also facilitating the targeted delivery of complex drug payloads, including nucleic acids. Aro Biotherapeutics is committed to advancing its wholly-owned pipeline of Centyrins, contributing to the field of genetic medicines.

SynOx Therapeutics

Series A in 2020
SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

InCarda Therapeutics

Series C in 2020
InCarda Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, focused on developing innovative therapies for cardiovascular diseases. The company specializes in an inhaled drug delivery system aimed at treating acute paroxysmal atrial fibrillation, allowing patients to administer treatment quickly during the onset of symptoms. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic medication designed to provide rapid relief from arrhythmic events. This method allows for effective medication delivery directly to cardiac tissue, which enhances treatment efficacy and simplifies the management of atrial arrhythmias. InCarda Therapeutics has completed Phase 1 clinical trials and is progressing through Phase 2 with its lead product.

Priothera

Series A in 2020
Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Doctrin

Series B in 2020
At Doctrin, they are passionate about improving healthcare. They strive to make patients healthier and happier, and healthcare professionals more effective at work. They achieve this by providing digital tools automating and simplifying as much of the patient journey as possible, for as many patients as possible.

Spruce Biosciences

Series B in 2020
Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Carisma Therapeutics

Series A in 2019
Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Fusion Pharmaceuticals

Series B in 2019
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Aprea

Series C in 2018
Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Oncorena

Venture Round in 2018
Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, specifically advanced or metastatic renal cancer. The company is focused on the compound orellanine, a toxin derived from certain mushroom species, which has demonstrated potent anti-tumor activity. Oncorena's primary objective is to confirm the efficacy and clinical benefits of orellanine in targeting renal proximal tubular epithelial cells that have transformed into cancer cells and formed metastases. By harnessing the selective properties of this compound, Oncorena aims to provide effective pharmacological solutions for patients suffering from advanced kidney cancer.

Precirix

Series A in 2018
Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

InCarda Therapeutics

Series B in 2018
InCarda Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, focused on developing innovative therapies for cardiovascular diseases. The company specializes in an inhaled drug delivery system aimed at treating acute paroxysmal atrial fibrillation, allowing patients to administer treatment quickly during the onset of symptoms. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic medication designed to provide rapid relief from arrhythmic events. This method allows for effective medication delivery directly to cardiac tissue, which enhances treatment efficacy and simplifies the management of atrial arrhythmias. InCarda Therapeutics has completed Phase 1 clinical trials and is progressing through Phase 2 with its lead product.

Modus Therapeutics

Series A in 2018
Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.

Carisma Therapeutics

Series A in 2018
Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Rainier Therapeutics

Series B in 2018
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

Doctrin

Venture Round in 2017
At Doctrin, they are passionate about improving healthcare. They strive to make patients healthier and happier, and healthcare professionals more effective at work. They achieve this by providing digital tools automating and simplifying as much of the patient journey as possible, for as many patients as possible.

Fusion Pharmaceuticals

Series A in 2017
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Carisma Therapeutics

Seed Round in 2017
Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Tisbury Pharmaceutical

Series A in 2017
Tisbury Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of therapies for the treatment of primary open angle glaucoma. Founded in 2017 and based in Beverly, Massachusetts, the company focuses on its clinical candidate, R-801, which aims to enhance fluid flow through the trabecular meshwork by utilizing redox catalysis and K+-ATP channel activation. This innovative approach targets the drainage openings in the eye, significantly reducing intraocular pressure in patients suffering from glaucoma.

Vivet Therapeutics

Series A in 2017
Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.

Rainier Therapeutics

Series B in 2017
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

Fusion Pharmaceuticals

Series A in 2017
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

BONESUPPORT

Venture Round in 2016
BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes designed to address fractures and bone voids resulting from trauma, infection, disease, or surgical interventions. The company's product portfolio includes CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, which are tailored for various orthopedic applications. CERAMENT V is an antibiotic eluting bone graft substitute that utilizes vancomycin to promote bone healing, while CERAMENT G employs gentamicin for similar purposes. The CERAMENT BONE VOID FILLER serves as a ceramic filler for gaps and voids in orthopedic settings. BONESUPPORT's mission is to improve the quality of life for patients with bone disorders, and the company operates additional locations in Germany, Switzerland, the United Kingdom, the United States, and India. Founded in 1999, BONESUPPORT AB is a subsidiary of Bonesupport Holding AB.

Aprea

Series B in 2016
Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Rainier Therapeutics

Series A in 2016
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

GenSight Biologics

Series B in 2015
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

LTB4 Sweden

Venture Round in 2015
LTB4 is developing a naturally occurring molecule stimulating the innate immunity system to target diseases such as infections and cancer.

Idea

Venture Round in 2015
IDEA AG is a biopharmaceutical company based in Munich, Germany, founded in 1993. The company specializes in the development and commercialization of non-invasive targeted therapeutics, primarily for dermatology and pain management. It focuses on delivering drugs through the skin using innovative Transfersome carriers, which facilitate the selective transport of established molecular weight drugs. One of its key products is Diractin, a ketoprofen formulation in a Transfersome gel designed to treat peripheral pain. IDEA AG aims to improve treatment outcomes for patients suffering from dermatological conditions and pain-related issues.

Altimmune

Post in 2015
Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies. Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors.

Strongbridge Biopharma

Venture Round in 2015
Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company markets Keveyis, an oral carbonic anhydrase inhibitor used to treat various forms of primary periodic paralysis in the United States. Its clinical pipeline includes Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Founded in 1996 and based in Trevose, Pennsylvania, Strongbridge Biopharma aims to build its portfolio around rare endocrine disorders and plans to utilize a focused sales strategy to reach its target markets. The company is also actively seeking to in-license or acquire complementary products to enhance its rare disease franchise.

Glionova

Series A in 2014
Glionova AB is a development stage biopharmaceutical company based in Stockholm, Sweden, founded in 2014. The company focuses on developing therapies for challenging cancers, particularly glioblastoma, which is a common and aggressive primary brain tumor. Glionova is advancing its lead product, GLN-1001, an orally bioavailable small molecule designed to induce selective cell death in glioblastoma cells while sparing normal brain tissue. In addition to its research and development efforts, Glionova aims to market its product through strategic partnerships with global pharmaceutical companies that specialize in oncology.

Strongbridge Biopharma

Venture Round in 2014
Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company markets Keveyis, an oral carbonic anhydrase inhibitor used to treat various forms of primary periodic paralysis in the United States. Its clinical pipeline includes Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Founded in 1996 and based in Trevose, Pennsylvania, Strongbridge Biopharma aims to build its portfolio around rare endocrine disorders and plans to utilize a focused sales strategy to reach its target markets. The company is also actively seeking to in-license or acquire complementary products to enhance its rare disease franchise.

Wilson Therapeutics

Series B in 2014
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients.

Rainier Therapeutics

Series A in 2014
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

Ultragenyx Pharmaceutical

Series B in 2012
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

BONESUPPORT

Venture Round in 2012
BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes designed to address fractures and bone voids resulting from trauma, infection, disease, or surgical interventions. The company's product portfolio includes CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, which are tailored for various orthopedic applications. CERAMENT V is an antibiotic eluting bone graft substitute that utilizes vancomycin to promote bone healing, while CERAMENT G employs gentamicin for similar purposes. The CERAMENT BONE VOID FILLER serves as a ceramic filler for gaps and voids in orthopedic settings. BONESUPPORT's mission is to improve the quality of life for patients with bone disorders, and the company operates additional locations in Germany, Switzerland, the United Kingdom, the United States, and India. Founded in 1999, BONESUPPORT AB is a subsidiary of Bonesupport Holding AB.

SpineVision

Venture Round in 2011
SpineVision S.A. is a spinal technology company that specializes in the design, development, and marketing of implants and instrumentation for spinal treatment. Established in 1999 and headquartered in Antony, France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States, the company focuses on addressing a diverse range of spinal pathologies, including degenerative disc disease, deformities, cervical disorders, trauma, and tumors. Its product portfolio includes advanced systems such as Flex+, X-PLUS, LUMIS, and P.L.U.S., which offer various stabilization options and surgical solutions. Additionally, SpineVision provides specialized systems like the C3 anterior cervical plate and UNI-Thread, enhancing surgical procedures and outcomes. The company's innovations are developed in collaboration with prominent neurological and orthopedic surgeons, resulting in over 20 patents that reflect its commitment to advancing spinal care.

BONESUPPORT

Venture Round in 2011
BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes designed to address fractures and bone voids resulting from trauma, infection, disease, or surgical interventions. The company's product portfolio includes CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, which are tailored for various orthopedic applications. CERAMENT V is an antibiotic eluting bone graft substitute that utilizes vancomycin to promote bone healing, while CERAMENT G employs gentamicin for similar purposes. The CERAMENT BONE VOID FILLER serves as a ceramic filler for gaps and voids in orthopedic settings. BONESUPPORT's mission is to improve the quality of life for patients with bone disorders, and the company operates additional locations in Germany, Switzerland, the United Kingdom, the United States, and India. Founded in 1999, BONESUPPORT AB is a subsidiary of Bonesupport Holding AB.

Ultragenyx Pharmaceutical

Series A in 2011
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Nexstim

Venture Round in 2011
Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

Cardoz

Series A in 2010
Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.

ABIONYX Pharma

Series C in 2010
ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

FerroKin Biosciences

Series B in 2010
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Oncos Therapeutics

Series C in 2010
Oncos Therapeutics develops new cancer therapies based on its next generation oncolytic viruses. The company's unique Advanced Therapy Access Program was started in 2007 for cancer patients in whom standard-of-care therapies have failed. Today, 200 patients have undergone individually tailored oncolytic virus therapy suggesting strong safety and efficacy. The program is based on extensive scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.

Immune Targeting Systems

Series A in 2010
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

Pulmonx

Series C in 2010
Pulmonx Corporation is a medical technology company that specializes in minimally invasive devices for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company's core offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema; the Chartis Pulmonary Assessment System, which assesses collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography images to aid in treatment planning. Pulmonx's solutions are intended for patients who remain symptomatic despite medical management and are either not candidates for or do not wish to pursue surgical options. The Zephyr Valve has received FDA pre-market approval and is supported by extensive clinical evidence demonstrating its benefits. Pulmonx serves a global market, with significant operations in the United States and various international regions, and has made a notable impact by treating thousands of patients with its innovative technology.

FerroKin Biosciences

Venture Round in 2009
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

BeneChill

Series C in 2009
BeneChill, Inc., a medical device company, develops non-invasive cooling technologies in the United States and Europe. The company develops non-invasive cooling technologies to improve patient outcomes after acute ischemic events, such as cardiac arrest, stroke, and traumatic brain injury. Its RhinoChill System focuses on reducing patient temperature. The company was founded in 2004 and is headquartered in San Diego, California.

Lumavita

Series A in 2009
Lumavita is an independent, specialty biopharmaceutical company focused on global development and commercialisation of novel anti-infectives for women’s health. Lumavita is based in Basel, Switzerland, home to a significant and growing biopharmaceutical sector.

Tengion

Series C in 2008
Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

ChemoCentryx

Series E in 2008
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.

Tengion

Series C in 2007
Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

Nexstim

Venture Round in 2007
Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

Immune Targeting Systems

Series A in 2007
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

OxThera

Venture Round in 2007
OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

CoreValve

Series C in 2007
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

BONESUPPORT

Venture Round in 2006
BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes designed to address fractures and bone voids resulting from trauma, infection, disease, or surgical interventions. The company's product portfolio includes CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, which are tailored for various orthopedic applications. CERAMENT V is an antibiotic eluting bone graft substitute that utilizes vancomycin to promote bone healing, while CERAMENT G employs gentamicin for similar purposes. The CERAMENT BONE VOID FILLER serves as a ceramic filler for gaps and voids in orthopedic settings. BONESUPPORT's mission is to improve the quality of life for patients with bone disorders, and the company operates additional locations in Germany, Switzerland, the United Kingdom, the United States, and India. Founded in 1999, BONESUPPORT AB is a subsidiary of Bonesupport Holding AB.

CoreValve

Venture Round in 2006
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

ABIONYX Pharma

Series B in 2006
ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Resistentia Pharmaceuticals

Series C in 2006
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Tengion

Series B in 2006
Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

Algeta

Series A in 2005
Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.

Alba Therapeutics

Series A in 2005
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland, dedicated to the discovery, development, and commercialization of treatments for autoimmune and inflammatory diseases. The company’s innovative approach centers on modifying epithelial permeability through compounds that regulate tight junctions in cell barriers. This technology has potential applications in various conditions, including celiac disease, asthma, chronic obstructive pulmonary disease (COPD), and acute lung injury. In addition, Alba Therapeutics focuses on therapeutic areas such as type 1 diabetes, inflammatory bowel disease (IBD), and mucosal vaccines, aiming to address a range of immune-mediated and inflammatory disorders.

ABIONYX Pharma

Series A in 2005
ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Tengion

Series A in 2005
Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.

CoreValve

Series B in 2005
CoreValve is a private company founded in 2001 by Jacques Seguin, M.D., Ph.D., a cardiac surgeon. The vision of the Company was to develop a technology that permits the replacement of failing aortic heart valves without surgical access. Developing the concept of a catheter-based aortic valve replacement procedure, the Company has rapidly advanced this technology from vision to reality. Today, more than 200 patients have experienced successful aortic valve replacement with the CoreValve ReValving™ procedure. CoreValve’s objective is to be the technological, clinical, and market leader in percutaneous heart valve replacement therapies. Current efforts are focused on percutaneous aortic valve replacement, but future efforts will relate to other minimally invasive structural heart disease treatments. CoreValve’s headquarters’ are in Irvine, California, an area renowned for the development of innovative heart valve technologies.

OxThera

Venture Round in 2005
OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

Jerini

Venture Round in 2005
- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Five Prime Therapeutics

Venture Round in 2005
Five Prime Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of innovative protein therapeutics. The company is advancing several product candidates, including Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b (FGFR2b), currently in Phase 3 clinical trials for gastric and gastroesophageal junction cancer. Other candidates include FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for various cancers, and FPT155, a soluble CD80 fusion protein enhancing T cell co-stimulation, also in Phase 1a/1b trials. Additionally, Cabiralizumab, which inhibits colony stimulating factor-1 receptor, is undergoing Phase Ia/Ib trials in combination with other therapies. The company employs its ProScreen Engine to systematically screen all relevant human proteins, enabling rapid and high-quality therapeutic development. Five Prime Therapeutics has established collaborations and license agreements with several pharmaceutical companies, enhancing its research and development capabilities. Founded in 2001, the company continues to focus on advancing novel therapies for challenging cancer indications.

Biolipox

Series C in 2005
Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Sopherion Therapeutics

Series B in 2004
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

ChemoCentryx

Series B in 2004
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.